ENANTA PHARMACEUTICALS INC (ENTA) is a publicly traded company in the Unknown sector. Across all available filings, 28 corporate insiders have executed 588 transactions totaling $116.8M, demonstrating a bearish sentiment with -$106.7M in net insider flow. The most recent transaction on Dec 5, 2025 involved a sale of 4,743 shares valued at $67.5K.
No significant insider buying has been recorded for ENTA in the recent period.
No significant insider selling has been recorded for ENTA in the recent period.
Based on recent SEC filings, insider sentiment for ENTA is bearish with an Insider Alignment Score of 4/100 and a net flow of -$106.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ENANTA PHARMACEUTICALS INC (ENTA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 28 insiders are actively trading ENTA stock, having executed 588 transactions in the past 90 days. The most active insider is Nathalie Adda (Executive), who has made 89 transactions totaling $25.0M.
Get notified when executives and directors at ENTA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | R. Luly Jay | Executive | Sale | 4,743 | $14.23 | $67.5K | |
| Dec 5, 2025 | Sun Or Yat | Executive | Sale | 2,390 | $14.23 | $34.0K | |
| Dec 5, 2025 | Lynn Kieffer Tara | Executive | Sale | 2,106 | $14.23 | $30.0K | |
| Dec 5, 2025 | Luu Brendan | Executive | Sale | 1,394 | $14.23 | $19.8K | |
| Dec 5, 2025 | T. Rottinghaus Scott | Executive | Sale | 798 | $14.23 | $11.4K | |
| Dec 5, 2025 | R. Trout Harry III | Executive | Sale | 542 | $14.23 | $7.7K | |
| Dec 5, 2025 | S. Capps Kathleen | Executive | Sale | 323 | $14.23 | $4.6K | |
| Dec 2, 2025 | R. Trout Harry III | Executive | Sale | 380 | $13.96 | $5.3K | |
| Dec 2, 2025 | S. Capps Kathleen | Executive | Sale | 207 | $13.96 | $2.9K | |
| Dec 1, 2025 | R. Luly Jay | Executive | Payment | 1,885 | $14.12 | $26.6K | |
| Dec 1, 2025 | Sun Or Yat | Executive | Payment | 753 | $14.12 | $10.6K | |
| Dec 1, 2025 | Lynn Kieffer Tara | Executive | Payment | 753 | $14.12 | $10.6K | |
| Dec 1, 2025 | Luu Brendan | Executive | Payment | 498 | $14.12 | $7.0K | |
| Dec 1, 2025 | R. Trout Harry III | Executive | Payment | 105 | $14.12 | $1.5K | |
| Dec 1, 2025 | S. Capps Kathleen | Executive | Payment | 85 | $14.12 | $1.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 266 | $111.7M | 77.0% |
Exercise(M) | 109 | $15.1M | 10.4% |
Payment(F) | 80 | $13.2M | 9.1% |
Purchase(P) | 13 | $5.1M | 3.5% |
Award(A) | 97 | $0 | 0.0% |
Conversion(C) | 23 | $0 | 0.0% |
Insider selling pressure at ENANTA PHARMACEUTICALS INC has increased, with 28 insiders executing 588 transactions across all time. Total sales of $111.7M significantly outpace purchases of $5.1M, resulting in a net outflow of $106.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.